Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Matthew D. Galsky et al.|The Lancet|2016Cited by 2.2k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Syed A. Hussain et al.|The Lancet|2017Cited by 1.4k
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)Enrique Grande, Rocio García‐Carbonero, Jaume Capdevila et al.|Annals of Oncology|2015Cited by 157
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Ken Herrmann, Alberto Bossi et al.|European Journal of Cancer|2023Cited by 156
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)Christian Rolfo, María José Serrano, Andrés F. Cardona et al.|Critical Reviews in Oncology/Hematology|2020Cited by 135